Adaptive Biotechnologies (NASDAQ:ADPT) reported a 21% year-on-year decline in total revenue to $37.9 million for Q3 2023 during its recent earnings call. The company announced a...
Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported third quarter EPS of $-0.35, worse than the analyst estimate of $-0.34. Revenue for the quarter came in at $37.92M...
Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported second quarter EPS of $-0.33, $0.02 better than the analyst estimate of $-0.35. Revenue for the quarter came in at...
Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported first quarter EPS of $-0.40, $0.03 worse than the analyst estimate of $-0.37. Revenue for the quarter came in at...
Adaptive Biotechnologies (NASDAQ:ADPT) reported Q4 EPS of ($0.28), $0.07 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $55.2 million versus the...
Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported fourth quarter EPS of $-0.28, $0.07 better than the analyst estimate of $-0.35. Revenue for the quarter came in at...
By Davit Kirakosyan Jefferies upgraded The Chef's Warehouse Inc (NASDAQ:CHEF) to Buy from Hold with a price target of $43.00, noting that the company is executing at a high level,...
how can this valuation (5bn vs. 100m revenues) be justified?
0
with the help of GlaxoSmithKline buy
0
they will be the ones who will find a vaccine.buy
0
is this just from the virus or is this a buy?
0
Hoy interpretais que es buen momento para comprar? . Después de vela bajista envolvente hay vela alcosta. Entendeís que puede tener tendencia alcista hasta 43,75$. Escribe tus pensamientos respecto al Adaptive Biotechnologies Corp
0
Going to drop like a rock this week! Already 340 million in debt in just the first quarter of this year alone.